China Resources Pharmaceutical Group Limited announced earnings guidance for the three months ended March 31, 2021. For the three months, the company expected net profit attributable to the shareholders range from RMB 55.48 million to RMB 72.13 million, representing an increase between 166% and 186% as compared to the net loss of RMB 83.87 million for the same period last year The change in results was mainly due to: Dong-E-E-Jiao adheres to the consumer-oriented principle, focuses on customer operation, accelerates digital transformation and establishes new growth logic. It will gradually enhance its organizational capabilities, steadily promote innovation in respect of technologies, products and marketing as well as re-branding in order to continuously create value for consumers' health. In the future, Dong-E-E-Jiao will pursue customer growth and retention, achieve incremental expansion and brand building, consolidate the leading position of core products in the market, and facilitate healthy growth in the market. Meanwhile, it will secure its leading status in the Chinese-style nourishing health sector, unleash the brand productivity, and deliver convenient, young and chic product experiences and services to consumers.